Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: A randomized controlled trial

Journal of Clinical Psychiatry

Volumn 71, Issue 7, 2010, Pages 915-922

  Zisook, Sidney ^a,b   Kasckow, John W ^c,d,e   Lanouette, Nicole M ^b   Golshan, Shahrokh ^a   Fellows, Ian ^a   Vahia, Ipsit ^b   Mohamed, Somaia ^f,g,h   Rao, Sanjai ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f Veterans Affairs Northeast Program Evaluation Center   (United States)

^g Veterans Integrated Service Network (VISN) 1 MIRECC   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDAL IDEATION; SYMPTOM; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; CITALOPRAM; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE;

EID: 77955294108     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05699gre     Document Type: Article

References (48)

1. Pompili M, Amador XF, Girardi P, et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry. 2007;6(1):10. (Pubitemid 46534768)
2. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull. 1990;16(4):571-589.
3. Allebeck P, Wistedt B. Mortality in schizophrenia: a ten-year follow-up based on the Stockholm County inpatient register. Arch Gen Psychiatry. 1986;43(7):650-653. (Pubitemid 16094176)
4. Breier A, Schreiber JL, Dyer J, et al. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48(3):239-246.
5. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry. 1993;163(2):183-189. (Pubitemid 23233086)
6. Allebeck P, Varla A, Wistedt B. Suicide and violent death among patients with schizophrenia. Acta Psychiatr Scand. 1986;74(1):43-49. (Pubitemid 16061286)
7. Heilä H, Isometsä ET, Henriksson MM, et al. Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sexspecific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry. 1997;154(9):1235-1242.
8. Montross LP, Kasckow J, Golshan S, et al. Suicidal ideation and suicide attempts among middle-aged and older patients with schizophrenia spectrum disorders and concurrent subsyndromal depression. J Nerv Ment Dis. 2008;196(12):884-890.
9. Tollefson GD, Sanger TM, Beasley CM, et al. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry. 1998;43(11):803-810.
10. Kay SR, Sevy S. Pyramidical model of schizophrenia. Schizophr Bull. 1990;16(3):537-545.
11. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull. 1999;25(1):157-171.
12. Zisook S, McAdams LA, Kuck J, et al. Depressive symptoms in schizophrenia. Am J Psychiatry. 1999;156(11):1736-1743.
13. Jin H, Zisook S, Palmer BW, et al. Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients. J Clin Psychiatry. 2001;62(10):797-803. (Pubitemid 33104666)
14. Micallef J, Fakra E, Blin O. Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006;32(2, Pt 1):263-269. (Pubitemid 43670236)
15. Kasckow JW, Zisook S. Co-occurring depressive symptoms in the older patient with schizophrenia. Drugs Aging. 2008;25(8):631-647.
16. Zisook S, Kasckow JW, Golshan S, et al. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry. 2009;70(4):562-571. Published online Dec 16, 2008.
17. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005;330(7488):385-389. (Pubitemid 40288822)
18. Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med. 2007;356(23):2343-2346.
19. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339(2):b2880.
20. Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ. 2009;180(3):291-297.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
22. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97-108.
23. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. (Pubitemid 29001829)
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
25. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;22(22):39-44. (Pubitemid 23355888)
26. Beck AT, Steer RA. Clinical predictors of eventual suicide: a 5- to 10-year prospective study of suicide attempters. J Affect Disord. 1989;17(3):203-209. (Pubitemid 19211192)
27. Beck AT, Steer RA, Ranieri WF. Scale for Suicide Ideation: psychometric properties of a self-report version. J Clin Psychol. 1988;44(4):499-505.
28. Pinninti N, Steer RA, Rissmiller DJ, et al. Use of the Beck Scale for suicide ideation with psychiatric inpatients diagnosed with schizophrenia, schizoaffective, or bipolar disorders. Behav Res Ther. 2002;40(9):1071-1079.
29. Beck AT, Brown GK, Steer RA. Psychometric characteristics of the Scale for Suicide Ideation with psychiatric outpatients. Behav Res Ther. 1997;35(11):1039-1046. (Pubitemid 27522426)
30. Lindenmayer JP, Czobor P, Alphs L, et al. InterSePT Study Group. The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res. 2003;63(1-2):161-170.
31. Meltzer HY, Alphs L, Green AI, et al. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91.
32. Bleuler M. On schizophrenic psychoses. Am J Psychiatry. 1979;136(11):1403-1409.
33. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol. 2007;22(5):249-267. (Pubitemid 47237544)
34. Keck PE Jr, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry. 2000;61(suppl 3):4-9.
35. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database. Am J Psychiatry. 2001;158(9):1449-1454. (Pubitemid 32847244)
36. Siris SG. Suicide and schizophrenia. J Psychopharmacol. 2001;15(2):127-135.
37. Caldwell CB, Gottesman II. Schizophrenia - a high-risk factor for suicide: clues to risk reduction. Suicide Life Threat Behav. 1992;22(4):479-493.
38. May PR, Van Putten T. Plasma levels of chlorpromazine in schizophrenia; a critical review of the literature. Arch Gen Psychiatry. 1978;35(9):1081-1087. (Pubitemid 8388598)
39. Kane JM, Fleischhacker WW, Hansen L, et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70(5):627-643.
40. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res. 2005;73(2-3):139-145. (Pubitemid 40103558)
41. Mann JJ. The neurobiology of suicide. Nat Med. 1998;4(1):25-30.
42. Meltzer H, Herbert Y, Bobo WV. Pharmacological management of suicide risk in schizophrenia. In: Tatarelli R, Pompili M, Girardi P, eds. Suicide in Schizophrenia. Hauppauge, NY: Nova Biomedical Books; 2007:275-302.
43. Hansen L. A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol. 2001;16(7):495-505. (Pubitemid 33014646)
44. Perlis RH, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry. 2007;64(6):689-697. (Pubitemid 46878669)
45. Hetrick S, Merry S, McKenzie J, et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2007;(3):CD004851. (Pubitemid 351805651)
46. Zisook S, Trivedi MH, Warden D, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J Affect Disord. 2009;117(1-2):63-73. Published online Feb 14, 2009.
47. Potkin SG, Alphs L, Hsu C, et al. InterSePT Study Group. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biol Psychiatry. 2003;54(4):444-452. (Pubitemid 37289451)
48. Geddes JR, Barbui C, Cipriani A. Risk of suicidal behaviour in adults taking antidepressants. BMJ. 2009;339(2):b3066.